Dr Niklas Sandler – member of Steering Group of SPARK Finland and one of the key figures of SPARK in Turku – is named as Nanoform’s new chief technology officer (CTO), a role that will see him combine pharmaceutical R&D with his commercial expertise to develop technological resources.

Nanoform Finland Limited is an innovative nanoparticle medicine enabling company. It works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization services.

Sandler joins Nanoform with extensive experience in both industry and academia, particularly in pharmaceutical product development and material science. His most recent role was Vice Rector, responsible for Research Affairs and Professor of Pharmaceutical Technology at Åbo Akademi University, Finland.

On behalf of SPARK Finland ecosystem we congratulate Niklas for a new appointment and wish all the best in the new job. We are looking forward to continue a fruitful collaboration also in this new arrangement.